Indaptus Therapeutics (NASDAQ:INDP) Sees Large Volume Increase – What’s Next?

Shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw unusually-strong trading volume on Thursday . Approximately 25,631,092 shares traded hands during trading, an increase of 10,529% from the previous session’s volume of 241,142 shares.The stock last traded at $4.8910 and had previously closed at $2.21.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Indaptus Therapeutics Price Performance

The firm has a market cap of $414.47 million, a P/E ratio of -0.24 and a beta of 1.25. The company’s 50 day moving average is $2.17 and its two-hundred day moving average is $2.21.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Friday, May 15th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.87) by $1.64.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.